Suppr超能文献

相似文献

1
Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.
FASEB J. 2011 Apr;25(4):1230-43. doi: 10.1096/fj.10-167627. Epub 2011 Jan 3.
2
Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.
Chem Biol. 2012 Dec 21;19(12):1579-88. doi: 10.1016/j.chembiol.2012.10.007.
3
Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity.
Biochem Biophys Res Commun. 2006 Dec 22;351(3):664-8. doi: 10.1016/j.bbrc.2006.10.090. Epub 2006 Oct 26.
5
Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.
Nat Struct Biol. 2001 Jul;8(7):611-5. doi: 10.1038/89653.
9
Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation.
Eur J Immunol. 2000 Nov;30(11):3190-8. doi: 10.1002/1521-4141(200011)30:11<3190::AID-IMMU3190>3.0.CO;2-E.
10
Rational design of novel HIV-1 entry inhibitors by RANTES engineering.
Vaccine. 2008 Jun 6;26(24):3008-15. doi: 10.1016/j.vaccine.2007.12.023. Epub 2008 Jan 10.

引用本文的文献

1
Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.
J Control Release. 2022 Aug;348:1028-1049. doi: 10.1016/j.jconrel.2022.06.037. Epub 2022 Jul 6.
3
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.
Pharmacol Ther. 2020 May;209:107503. doi: 10.1016/j.pharmthera.2020.107503. Epub 2020 Feb 14.
5
Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5.
Antimicrob Agents Chemother. 2014 Oct;58(10):6215-23. doi: 10.1128/AAC.03559-14. Epub 2014 Aug 11.
7
Physical exercise reduces the expression of RANTES and its CCR5 receptor in the adipose tissue of obese humans.
Mediators Inflamm. 2014;2014:627150. doi: 10.1155/2014/627150. Epub 2014 Apr 17.
8
The CD8-derived chemokine XCL1/lymphotactin is a conformation-dependent, broad-spectrum inhibitor of HIV-1.
PLoS Pathog. 2013;9(12):e1003852. doi: 10.1371/journal.ppat.1003852. Epub 2013 Dec 26.
10
Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.
Mol Pharm. 2013 Oct 7;10(10):3564-73. doi: 10.1021/mp3007242. Epub 2013 Aug 26.

本文引用的文献

1
An all atom force field for simulations of proteins and nucleic acids.
J Comput Chem. 1986 Apr;7(2):230-252. doi: 10.1002/jcc.540070216.
2
A biophysical insight into the RANTES-glycosaminoglycan interaction.
Biochim Biophys Acta. 2009 Apr;1794(4):577-82. doi: 10.1016/j.bbapap.2009.01.001.
3
Maraviroc for previously treated patients with R5 HIV-1 infection.
N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.
4
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
J Biol Chem. 2008 Apr 25;283(17):11126-34. doi: 10.1074/jbc.M800200200. Epub 2008 Feb 26.
5
The Monte Carlo method.
J Am Stat Assoc. 1949 Sep;44(247):335-41. doi: 10.1080/01621459.1949.10483310.
7
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids.
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83. doi: 10.1093/nar/gkm216. Epub 2007 Apr 22.
8
Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity.
Biochem Biophys Res Commun. 2006 Dec 22;351(3):664-8. doi: 10.1016/j.bbrc.2006.10.090. Epub 2006 Oct 26.
9
Biology of CCR5 and its role in HIV infection and treatment.
JAMA. 2006 Aug 16;296(7):815-26. doi: 10.1001/jama.296.7.815.
10
HIV and the chemokine system: 10 years later.
EMBO J. 2006 Feb 8;25(3):447-56. doi: 10.1038/sj.emboj.7600947. Epub 2006 Jan 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验